STOCKHOLM, SWEDEN / RankWire.AI / – Karl Deisseroth, Peter Hegemann and Georg Nagel won the 2026 Nobel Prize in Physiology or Medicine for discoveries that established optogenetics. The Nobel Assembly at Karolinska Institutet announced the award on October 5. Their work gave scientists a precise way to control selected nerve cells with light. The method now plays a central role in research on brain circuits, behaviour, memory and disease. It has become one of neuroscience’s most important experimental tools.
Hegemann and Nagel helped uncover how channelrhodopsin works in the green alga Chlamydomonas. The protein forms a light-sensitive channel in a cell membrane. Blue light opens that channel and allows charged ions to move through it. This process can trigger electrical activity inside a cell. Their experiments showed that scientists could place channelrhodopsin in other cells and make those cells respond to light. That finding created a foundation for controlling cell activity with flashes of light.
Deisseroth then adapted the discovery for neuroscience. In 2005, he showed that channelrhodopsin could make rat nerve cells respond to blue light. His research demonstrated that light could trigger electrical signals in selected neurons. Later work showed that the technique also functioned in living animals. Those results helped turn optogenetics into a practical tool for studying how specific brain circuits control activity and behaviour. The approach gave researchers far greater precision than many earlier methods.
Light control reshapes brain research
Optogenetics combines genetic targeting with light-sensitive proteins. Researchers can use the method to activate or silence defined groups of nerve cells. That control helps scientists test how individual circuits contribute to movement, learning, emotion and memory. The Nobel Assembly said the technique transformed research on the living brain. It also gave laboratories a way to connect activity in selected cells with measurable changes in behaviour. Scientists can study targeted cells without stimulating broad areas of tissue at the same time.
Scientists now use optogenetics in studies of Parkinson’s disease, epilepsy, depression, addiction and other disorders. Researchers are also testing related methods for severe vision loss. Some experimental approaches aim to make retinal cells responsive to light again. These medical applications remain under study and do not yet serve as standard treatments. The technique’s strongest current role remains in research, where it helps scientists examine complex biological systems with high precision. Its use now extends beyond neuroscience into other areas of cell biology.
Three scientists share Nobel medicine prize
Deisseroth works at Stanford University and is an investigator with the Howard Hughes Medical Institute in the United States. Hegemann works at Humboldt University of Berlin. Nagel works at the University of Würzburg in Germany. The three laureates will share 12 million Swedish kronor. Their work represents separate but connected steps in the development of modern optogenetics. Those steps span the discovery of light-sensitive proteins, their characterization and their use for controlling nerve cells.
The award recognizes a scientific path that began with a simple organism and changed modern brain research. Channelrhodopsin provided the molecular switch that made precise light control possible. Deisseroth’s work helped bring that switch into nerve cells and living brains. Researchers now use optogenetics across neuroscience and other areas of biology. The laureates will receive their Nobel medals and diplomas in Stockholm on December 10. The ceremony takes place on the anniversary of Alfred Nobel’s death, following a long-standing Nobel tradition.